465 related articles for article (PubMed ID: 32111081)
1. Mutant p53-Associated Molecular Mechanisms of ROS Regulation in Cancer Cells.
Cordani M; Butera G; Pacchiana R; Masetto F; Mullappilly N; Riganti C; Donadelli M
Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111081
[TBL] [Abstract][Full Text] [Related]
2. Mutant p53 induces SIRT3/MnSOD axis to moderate ROS production in melanoma cells.
Torrens-Mas M; Cordani M; Mullappilly N; Pacchiana R; Riganti C; Palmieri M; Pons DG; Roca P; Oliver J; Donadelli M
Arch Biochem Biophys; 2020 Jan; 679():108219. PubMed ID: 31812668
[TBL] [Abstract][Full Text] [Related]
3. Mutant p53 and mTOR/PKM2 regulation in cancer cells.
Dando I; Cordani M; Donadelli M
IUBMB Life; 2016 Sep; 68(9):722-6. PubMed ID: 27385486
[TBL] [Abstract][Full Text] [Related]
4. Interaction of p53 with tumor suppressive and oncogenic signaling pathways to control cellular reactive oxygen species production.
Ladelfa MF; Toledo MF; Laiseca JE; Monte M
Antioxid Redox Signal; 2011 Sep; 15(6):1749-61. PubMed ID: 20919943
[TBL] [Abstract][Full Text] [Related]
5. Mutant p53 blocks SESN1/AMPK/PGC-1α/UCP2 axis increasing mitochondrial O
Cordani M; Butera G; Dando I; Torrens-Mas M; Butturini E; Pacchiana R; Oppici E; Cavallini C; Gasperini S; Tamassia N; Nadal-Serrano M; Coan M; Rossi D; Gaidano G; Caraglia M; Mariotto S; Spizzo R; Roca P; Oliver J; Scupoli MT; Donadelli M
Br J Cancer; 2018 Oct; 119(8):994-1008. PubMed ID: 30318520
[TBL] [Abstract][Full Text] [Related]
6. Gain of function mutant p53 protein activates AKT through the Rac1 signaling to promote tumorigenesis.
Yue X; Wu F; Li Y; Liu J; Boateng M; Mandava K; Zhang C; Feng Z; Gao J; Hu W
Cell Cycle; 2020 Jun; 19(11):1338-1351. PubMed ID: 32275841
[TBL] [Abstract][Full Text] [Related]
7. Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis.
Stein Y; Rotter V; Aloni-Grinstein R
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817996
[TBL] [Abstract][Full Text] [Related]
8. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
[TBL] [Abstract][Full Text] [Related]
9. p53-R273H Sustains ROS, Pro-Inflammatory Cytokine Release and mTOR Activation While Reducing Autophagy, Mitophagy and UCP2 Expression, Effects Prevented by wtp53.
Romeo MA; Gilardini Montani MS; Benedetti R; Arena A; D'Orazi G; Cirone M
Biomolecules; 2021 Feb; 11(3):. PubMed ID: 33668399
[No Abstract] [Full Text] [Related]
10. Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species.
Kalo E; Kogan-Sakin I; Solomon H; Bar-Nathan E; Shay M; Shetzer Y; Dekel E; Goldfinger N; Buganim Y; Stambolsky P; Goldstein I; Madar S; Rotter V
J Cell Sci; 2012 Nov; 125(Pt 22):5578-86. PubMed ID: 22899716
[TBL] [Abstract][Full Text] [Related]
11. Gain-of-function mutant p53 in cancer progression and therapy.
Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
[TBL] [Abstract][Full Text] [Related]
12. Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes.
Redman-Rivera LN; Shaver TM; Jin H; Marshall CB; Schafer JM; Sheng Q; Hongo RA; Beckermann KE; Wheeler FC; Lehmann BD; Pietenpol JA
Nat Commun; 2021 Aug; 12(1):5184. PubMed ID: 34465782
[TBL] [Abstract][Full Text] [Related]
13. The vicious cycle between ferritinophagy and ROS production triggered EMT inhibition of gastric cancer cells was through p53/AKT/mTor pathway.
Xu Z; Feng J; Li Y; Guan D; Chen H; Zhai X; Zhang L; Li C; Li C
Chem Biol Interact; 2020 Sep; 328():109196. PubMed ID: 32687844
[TBL] [Abstract][Full Text] [Related]
14. New therapeutic strategies to treat human cancers expressing mutant p53 proteins.
Blandino G; Di Agostino S
J Exp Clin Cancer Res; 2018 Feb; 37(1):30. PubMed ID: 29448954
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation.
Shetzer Y; Molchadsky A; Rotter V
Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27235476
[TBL] [Abstract][Full Text] [Related]
16. Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism.
Eriksson M; Ambroise G; Ouchida AT; Lima Queiroz A; Smith D; Gimenez-Cassina A; Iwanicki MP; Muller PA; Norberg E; Vakifahmetoglu-Norberg H
Mol Cell Biol; 2017 Dec; 37(24):. PubMed ID: 28993478
[No Abstract] [Full Text] [Related]
17. Reactive oxygen species regulation of autophagy in cancer: implications for cancer treatment.
Li L; Ishdorj G; Gibson SB
Free Radic Biol Med; 2012 Oct; 53(7):1399-410. PubMed ID: 22820461
[TBL] [Abstract][Full Text] [Related]
18. Tumor suppressor p53 and metabolism.
Liu J; Zhang C; Hu W; Feng Z
J Mol Cell Biol; 2019 Apr; 11(4):284-292. PubMed ID: 30500901
[TBL] [Abstract][Full Text] [Related]
19. Mutant p53 partners in crime.
Kim MP; Lozano G
Cell Death Differ; 2018 Jan; 25(1):161-168. PubMed ID: 29099488
[TBL] [Abstract][Full Text] [Related]
20. p53 gain-of-function mutations increase Cdc7-dependent replication initiation.
Datta A; Ghatak D; Das S; Banerjee T; Paul A; Butti R; Gorain M; Ghuwalewala S; Roychowdhury A; Alam SK; Das P; Chatterjee R; Dasgupta M; Panda CK; Kundu GC; Roychoudhury S
EMBO Rep; 2017 Nov; 18(11):2030-2050. PubMed ID: 28887320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
